Privia Health (PRVA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $22.62, +4.38% vs the prior close of $21.67.
- Volume 2.00M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PRVA jumps 4.4% to $22.62, a 1-month high, 5 up days in a row. Closed at $22.62, +4.38% vs the prior close of $21.67. Day range $21.89–$22.73, opened at $21.97.
PRVA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — PRVA jumps 4.4% to $22.62, a 1-month high, 5 up days in a row
- Closed at $22.62, +4.38% vs the prior close of $21.67. Day range $21.89–$22.73, opened at $21.97.
- Volume was 2.00M shares, 1.5x its 50-day average of 1.31M.
- Price is +8.9% vs its 50-day average ($20.78) and -0.5% vs its 200-day average ($22.74).
- 52-week range $18.92–$28.82; today's close sits at 37% of that range, 21.5% below the 52-week high.
- That makes 5 straight gains.
Oct 14, 2026 — PRVA ends flat (+0.1%) to $21.67, a 1-month high, 4 up days in a row
- Closed at $21.67, +0.09% vs the prior close of $21.65. Day range $21.46–$21.97, opened at $21.48.
- Volume was 1.30M shares, 1.0x its 50-day average of 1.30M.
- Price is +4.2% vs its 50-day average ($20.80) and -4.7% vs its 200-day average ($22.75).
- 52-week range $18.92–$28.82; today's close sits at 28% of that range, 24.8% below the 52-week high.
- That makes 4 straight gains.
Oct 13, 2026 — PRVA rises 0.9% to $21.65, a 1-month high, 3 up days in a row
- Closed at $21.65, +0.93% vs the prior close of $21.45. Day range $21.37–$22.05, opened at $21.57.
- Volume was 1.95M shares, 1.5x its 50-day average of 1.28M.
- Price is +3.9% vs its 50-day average ($20.84) and -4.9% vs its 200-day average ($22.76).
- 52-week range $18.92–$28.82; today's close sits at 28% of that range, 24.9% below the 52-week high.
- That makes 3 straight gains.
Oct 12, 2026 — PRVA rises 2.9% to $21.45, a 1-month high
- Closed at $21.45, +2.88% vs the prior close of $20.85. Day range $20.84–$21.76, opened at $20.89.
- Volume was 1.41M shares, 1.1x its 50-day average of 1.27M.
- Price is +2.7% vs its 50-day average ($20.89) and -5.8% vs its 200-day average ($22.77).
- 52-week range $18.92–$28.82; today's close sits at 26% of that range, 25.6% below the 52-week high.
Oct 9, 2026 — PRVA jumps 3.3% to $20.85
- Closed at $20.85, +3.27% vs the prior close of $20.19. Day range $20.23–$20.94, opened at $20.31.
- Volume was 1.13M shares, 0.9x its 50-day average of 1.26M.
- Price is -0.4% vs its 50-day average ($20.93) and -8.5% vs its 200-day average ($22.78).
- 52-week range $18.92–$28.82; today's close sits at 20% of that range, 27.7% below the 52-week high.
Oct 8, 2026 — PRVA dips 0.5% to $20.19
- Closed at $20.19, -0.54% vs the prior close of $20.30. Day range $20.09–$20.43, opened at $20.27.
- Volume was 1.56M shares, 1.2x its 50-day average of 1.25M.
- Price is -3.8% vs its 50-day average ($20.99) and -11.4% vs its 200-day average ($22.80).
- 52-week range $18.92–$28.82; today's close sits at 13% of that range, 29.9% below the 52-week high.
Oct 7, 2026 — PRVA ends flat (+0.1%) to $20.30
- Closed at $20.30, +0.10% vs the prior close of $20.28. Day range $20.00–$20.83, opened at $20.17.
- Volume was 1.61M shares, 1.3x its 50-day average of 1.24M.
- Price is -3.7% vs its 50-day average ($21.07) and -11.0% vs its 200-day average ($22.81).
- 52-week range $18.92–$28.82; today's close sits at 14% of that range, 29.6% below the 52-week high.
Oct 6, 2026 — PRVA dips 0.8% to $20.28
- Closed at $20.28, -0.83% vs the prior close of $20.45. Day range $20.26–$20.88, opened at $20.64.
- Volume was 1.08M shares, 0.9x its 50-day average of 1.23M.
- Price is -4.2% vs its 50-day average ($21.16) and -11.2% vs its 200-day average ($22.83).
- 52-week range $18.92–$28.82; today's close sits at 14% of that range, 29.6% below the 52-week high.
Oct 5, 2026 — PRVA rises 0.7% to $20.45, 4 up days in a row
- Closed at $20.45, +0.74% vs the prior close of $20.30. Day range $20.22–$20.55, opened at $20.37.
- Volume was 1.34M shares, 1.1x its 50-day average of 1.23M.
- Price is -3.8% vs its 50-day average ($21.25) and -10.5% vs its 200-day average ($22.85).
- 52-week range $18.92–$28.82; today's close sits at 15% of that range, 29.0% below the 52-week high.
- That makes 4 straight gains.
Oct 2, 2026 — PRVA rises 1.3% to $20.30, 3 up days in a row
- Closed at $20.30, +1.35% vs the prior close of $20.03. Day range $19.96–$20.33, opened at $20.27.
- Volume was 1.28M shares, 1.0x its 50-day average of 1.22M.
- Price is -4.9% vs its 50-day average ($21.35) and -11.2% vs its 200-day average ($22.87).
- 52-week range $18.92–$28.82; today's close sits at 14% of that range, 29.6% below the 52-week high.
- That makes 3 straight gains.
PRVA latest news & SEC filings
Every SEC filing by or about PRVA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 8, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: $9.05M (prior year $2.69M) (+236.7% vs Jun 30, 2025)
- Diluted EPS: $0.07 (prior year $0.02) (+250.0% vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mountcastle David sold 21,275 shares at $27.67 (≈$588.68K) on Jul 9, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mountcastle David sold 600 shares at $27.57 (≈$16.54K) on Jul 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Morris Matthew Shawn sold 53,722 shares at $27.24 (≈$1.46M) on Jul 6, 2026
- Morris Matthew Shawn sold 59,037 shares at $27.33 (≈$1.61M) on Jul 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade PRVA
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.37% (largest 4.4%).
- Liquidity: about 1.43M shares (≈$32.24M) trade per day on average.
- 52-week position: $22.62 vs a range of $18.92–$28.82 (37% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: David Mountcastle sold 21,275 shares on Jul 9, 2026.
- Latest filings: 8-K Aug 18, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 127.73M shares outstanding (Jul 31, 2026), +4.1% vs a year earlier.
- Listing: Nasdaq · industry: Services-Health Services.
PRVA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 21.97 | 22.73 | 21.89 | 22.62 | 2.00M |
| Oct 14, 2026 | 21.48 | 21.97 | 21.46 | 21.67 | 1.30M |
| Oct 13, 2026 | 21.57 | 22.05 | 21.37 | 21.65 | 1.95M |
| Oct 12, 2026 | 20.89 | 21.76 | 20.84 | 21.45 | 1.41M |
| Oct 9, 2026 | 20.31 | 20.94 | 20.23 | 20.85 | 1.13M |
| Oct 8, 2026 | 20.27 | 20.43 | 20.09 | 20.19 | 1.56M |
| Oct 7, 2026 | 20.17 | 20.83 | 20.00 | 20.30 | 1.61M |
| Oct 6, 2026 | 20.64 | 20.88 | 20.26 | 20.28 | 1.08M |
| Oct 5, 2026 | 20.37 | 20.55 | 20.22 | 20.45 | 1.34M |
| Oct 2, 2026 | 20.27 | 20.33 | 19.96 | 20.30 | 1.28M |
| Oct 1, 2026 | 19.73 | 20.38 | 19.49 | 20.03 | 1.41M |
| Sep 30, 2026 | 19.73 | 20.05 | 19.50 | 19.69 | 1.34M |
| Sep 29, 2026 | 19.77 | 19.77 | 19.27 | 19.62 | 998.70K |
| Sep 28, 2026 | 19.67 | 20.12 | 19.50 | 19.87 | 1.40M |
| Sep 25, 2026 | 19.36 | 19.88 | 19.28 | 19.71 | 1.39M |
| Sep 24, 2026 | 19.10 | 19.40 | 18.92 | 19.39 | 1.48M |
| Sep 23, 2026 | 19.39 | 19.53 | 18.98 | 19.10 | 980.10K |
| Sep 22, 2026 | 19.53 | 19.90 | 19.42 | 19.46 | 1.09M |
| Sep 21, 2026 | 19.86 | 20.45 | 19.42 | 19.54 | 980.20K |
| Sep 18, 2026 | 19.95 | 20.17 | 19.76 | 19.85 | 2.76M |
About Privia Health
Privia Health (PRVA) is listed on the Nasdaq and classified by the SEC under “Services-Health Services”. Its business address is in ARLINGTON, VA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1759655.
PRVA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Lance Berberian | Director | May 22, 2026 |
| Nancy G Cocozza | Director | May 22, 2026 |
| Opella Finley Ernest | Director | Sep 3, 2026 |
| David P King | Director | May 22, 2026 |
| Pamela O Kimmet | Director | May 22, 2026 |
| Thomas A Mccarthy | Director | May 22, 2026 |
| Parth Mehrotra | Chief Executive Officer | May 13, 2026 |
| Matthew Shawn Morris | Director | Jul 7, 2026 |
| Jaewon Ryu | Director | May 22, 2026 |
| Francis S Jr Soistman | Director | May 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Edward C Fargis | EVP & General Counsel | Mar 12, 2026 |
| Parth Mehrotra | Chief Executive Officer | May 13, 2026 |
| David Mountcastle | EVP & Chief Financial Officer | Jul 13, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 9, 2026 | David Mountcastle | Sale | 21,275 | $27.67 |
| Jul 7, 2026 | David Mountcastle | Sale | 600 | $27.57 |
| Jul 6, 2026 | Matthew Shawn Morris | Sale | 53,722 | $27.24 |
| Jul 2, 2026 | Matthew Shawn Morris | Sale | 59,037 | $27.33 |
| Jul 2, 2026 | David Mountcastle | Sale | 24,734 | $27.50 |
| Jul 1, 2026 | Matthew Shawn Morris | Sale | 37,041 | $26.93 |
| Jul 1, 2026 | Matthew Shawn Morris | Sale | 45,634 | $26.52 |
| Jun 30, 2026 | Matthew Shawn Morris | Sale | 52,823 | $25.72 |
| Jun 29, 2026 | Matthew Shawn Morris | Sale | 63,212 | $25.33 |
| Jun 26, 2026 | Matthew Shawn Morris | Sale | 88,110 | $25.33 |
| Jun 26, 2026 | David Mountcastle | Sale | 17,196 | $25.18 |
| May 12, 2026 | Parth Mehrotra | Sale | 15,647 | $22.64 |
| May 11, 2026 | Parth Mehrotra | Sale | 105,439 | $22.55 |
| May 11, 2026 | David Mountcastle | Sale | 3,385 | $22.60 |
| May 4, 2026 | David Mountcastle | Sale | 1,206 | $25.00 |
PRVA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $22.92M | 0.18 | $163.40M |
| Dec 31, 2024 | — | $14.38M | 0.11 | $109.28M |
| Dec 31, 2023 | — | $23.08M | 0.19 | $80.78M |
| Dec 31, 2022 | — | $-8.59M | -0.08 | $47.20M |
| Dec 31, 2021 | — | $-188.23M | -1.83 | $55.06M |
Latest balance sheet: total assets $1.49B, total liabilities $650.51M, cash $412.20M (as of Jun 30, 2026).
PRVA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $22.00 |
| May 7, 2026 | 8-K Item 2.02 (results) | $23.99 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $24.91 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $23.98 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $19.51 |
| May 8, 2025 | 8-K Item 2.02 (results) | $25.07 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $25.46 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $22.53 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 3, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Health Services
GeneDx (WGS)LifeStance Health (LFST)Omada Health (OMDA)U S Physical Therapy (USPH)Pennant (PNTG)Strata Critical Medical (SRTA)InnovAge (INNV)EUDA Health (EUDA)DocGo (DCGO)P3 Health Partners (PIII)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on PRVA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.